US 11,685,733 B2
Compounds for treating Rac-GTPase mediated disorder
David A Williams, Dover, MA (US)
Assigned to Children's Medical Center Corporation, Boston, MA (US)
Appl. No. 16/962,724
Filed by Children's Medical Center Corporation, Boston, MA (US)
PCT Filed Jan. 17, 2019, PCT No. PCT/US2019/014035
§ 371(c)(1), (2) Date Jul. 16, 2020,
PCT Pub. No. WO2019/143833, PCT Pub. Date Jul. 25, 2019.
Claims priority of provisional application 62/619,455, filed on Jan. 19, 2018.
Prior Publication US 2020/0347044 A1, Nov. 5, 2020
Int. Cl. C07D 413/14 (2006.01); A61P 35/02 (2006.01); A61K 9/00 (2006.01)
CPC C07D 413/14 (2013.01) [A61P 35/02 (2018.01); A61K 9/0019 (2013.01)] 12 Claims
 
1. A compound of formula (I) or a salt thereof:

OG Complex Work Unit Chemistry
wherein
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, or 4;
each of R1, R2, R3, R4, and R5, independently, is H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, heteroaryl, halo, ORa, SRa, COORa, OC(O)Ra, C(O)Ra, C(O)NRaRb, S(O)2NRaRb, or NRaRb;
each of R6, independently, is C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, heteroaryl, halo, ORa, SRa, COORa, OC(O)Ra, C(O)Ra, C(O)NRaRb, S(O)2NRaRb, or NRaRb;
each of R7, independently, is C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, heteroaryl, halo, ORa, SRa, COORa, OC(O)Ra, C(O)Ra, C(O)NRaRb, S(O)2NRaRb, or NRaRb;
each Ra, independently, is H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, or heteroaryl; and
each Rb, independently, is H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, or heteroaryl.